方法：回顾性分析40例最佳矫正视力(BCVA，小数视力)≤0.6，黄斑中心凹厚度(CMT)≥250μm的视网膜静脉阻塞性黄斑水肿患者，分别进行玻璃体腔注射TA(22例，4mg，0.1mL)或LU(18例，0.5mg，0.05mL)治疗。比较两种药物治疗前和治疗后1， 2wk； 1， 2， 3，6mo两组CMT与BCVA的改变情况

结果：两组在治疗后视力明显提高，术后各时间点均较术前具有显著改变(P<0.05)， TA组治疗后1mo视力最好(BCVA，logMAR=0.30±0.20)，LU组治疗后2mo视力最好(BCVA，logMAR=0.21±0.10)，两组在治疗后黄斑水肿明显减轻，CMT明显降低，术后各时间点均具有统计学意义(P<0.05)，两组治疗后2mo时黄斑水肿程度最低(TA组CMT=274.45±141.81μm，LU组CMT=225.83±22.86μm)。BCVA(小数视力)与CMT呈负相关。各项指标两组间均无统计学差异。

结论： 玻璃体腔注射TA及LU治疗视网膜静脉阻塞性黄斑水肿均可减轻黄斑水肿和改善视力，两者治疗效果无显著差异。

METHODS: Forty cases of retinal vein occlusion with macular edema were analyzed retrospectively, all the case's best corrected visual acuity(BCVA)≤0.6, fovea centralis thickness(CMT)≥250μm. All the eyes were treated with intravitreal injection of TA(22 cases, 4mg, 0.1mL)or LU(18 cases, 0.5mg, 0.05mL). The follow-up time was 1, 2wk, 1, 2, 3 and 6mo. BCVA and CMT were measured.

RESULTS:The two group's BCVA were significantly improved than preoperation. There were significant differences at each follow-up time compared with preoperation(P<0.05). The best BCVA after intravitreal injection of TA was showed at 1mo(logMAR=0.30±0.20), while the intravitreal injection of LU was 2mo(logMAR=0.21±0.10). The two group's CMT were significantly relieved than preoperation. There were significant differences at each follow-up time compared with preoperation(P<0.05). The best CMT after intravitreal injection of TA and LU were all showed at 2mo(TA CMT=274.45±141.81μm, LU CMT=225.83±22.86μm).The BCVA is negatively related with CMT. The BCVA and CMT had no statistical difference between the two groups.

CONCLUSION: Intravitreal injection of TA and LU in the treatment of macular edema in retinal vein occlusion can reduce macular edema and improve the visual activity. There is no significant difference between the two treatments.